Intralytix, Inc. Bacteriophage Home

Intralytix, Inc. is focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings. Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are natural enemies of disease causing bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting the rest of the microbiome, ensuring an unprecedented level of safety for an antimicrobial.

Press Releases

Intralytix Launches Phase 1/2a Phage Therapy Trial of Its VRELysin™ Phage Preparation, to Assess Safety and Efficacy in Healthy and VRE-Colonized Subjects

09/12/2023 1 week ago

Columbia, Maryland - September 12, 2023 - Intralytix, Inc. today announced the launch of a Phase 1/2a clinical trial to assess the safety and efficacy of its phage therapy product VRELysin™ in significantly reducing or eliminating vancomycin-resistant enterococci (VRE) levels in the human gastrointestinal tract.

Intralytix's EcoActive Phase 1/2a Phage Trial Begins Enrollment at Johns Hopkins University in the Baltimore, Maryland Metro Area

08/01/2023 1 month ago

Intralytix, Inc. announced today that the clinical trial “A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia coli (AIEC) in patients with inactive Crohn’s disease (CD),” will begin enrolling at the Johns Hopkins University (JHU) at various locations throughout the Baltimore metro area in Maryland (USA).

Full Enrollment of Phase 1 Safety Trial Achieved of Intralytix Phage Product to Prevent Illness Caused by Shigella

03/24/2023 5 months ago

Intralytix, Inc. today announced successful, full enrollment of its Phase 1 clinical trial at the University of Maryland’s School of Medicine (UMSOM) in Baltimore under the direction of Dr. Wilbur Chen, Professor of Medicine and Chief of Adult Clinical Studies at UMSOM’s Center for Vaccine Development and Global Health (CVD).

... Continued In News

Around the World

H.C. Wainwright & Co., LLC hosts the First Annual Bacteriophage Conference

11/30/2022 9 months ago

On November 30, 2022, H.C. Wainwright & Co., LLC hosted the First Annual Bacteriophage Conference to highlight what H.C. Wainwright & Co. believes to be a major pending inflection point in the field. Intralytix was one of the phage companies featured at the conference, with our President and CEO, Dr. Alexander "Sandro" Sulakvelidze presenting.

The State of Phage Therapy

03/02/2022 1 year ago

Bacteriophages could be crucial weapons in the fight against antibiotic-resistant bacteria.

How bacteria-killing viruses are being used to keep food safe

01/12/2022 1 year ago

Bacteria-killing viruses, called bacteriophages, are increasingly being used to destroy harmful microbes during food processing, to stop food rotting and to treat plant and animal diseases on farms.

Food Poisoning Sickens Millions a Year. Now, a Surprising Weapon Is Helping Protect Against Contamination

10/27/2021 1 year ago

Every year, one in seven people in America comes down with a foodborne illness, typically caused by a bacterial pathogen, including E.Coli, listeria, salmonella, or campylobacter

... Continued In News

Frequently Asked

What is a bacteriophage?

A bacteriophage (also known as a phage) is a type of virus that infects and replicates within bacteria. Bacteriophages are composed of a nucleic acid molecule (DNA or RNA) surrounded by a protein coat, and they are specific to certain types of bacteria.

Bacteriophages are found in many different environments, including soil, water, and the human gut. They play a significant role in the natural balance of bacteria in these environments and can be used as a tool to control bacterial infections in humans.

How do bacteriophages work?

Bacteriophages work by attaching to the surface of a bacterial cell and injecting their genetic material into the cell. The phage's genetic material then takes over the machinery of the bacterial cell, replicating itself and eventually causing the cell to burst and release new phages. This process is known as the lytic cycle, and it can lead to the rapid destruction of the bacterial population.

Bacteriophages have been studied for their potential use as antimicrobial agents, and some have been developed into phage therapies for the treatment of bacterial infections that are resistant to traditional antibiotics.

... Continued In FAQ

Products

ListShield™

Targets Listeria monocytogenes contamination in foods and food processing facilities.

U.S. Patent No. 7,507,571; 8,685,697

Star-K Kosher Certification:Kosher Certified, Islamic Food and Nutrition Council of America:Halal Certified, Organic Materials Review Institute:OMRI Listed®, FDA:GRN 528, FDA:21 CFR 172.785, FSIS:Directive 7120.1, Health Canada:iLONO, Israel Ministry of Health:Ref: 70275202

EcoShield™ PX

Targets Shiga toxin producing Escherichia coli (STEC), including O157:H7 and all “big six” STEC serotypes.

U.S. Patent No. 7,625,741; 7,635,584; 7,625,556

Star-K Kosher Certification:Kosher Certified, Islamic Food and Nutrition Council of America:Halal Certified, Organic Materials Review Institute:OMRI Listed®, FDA:FCN 1018, FSIS:Directive 7120.1, Health Canada:iLONO, Israel Ministry of Health:Ref: 70275202

SalmoFresh™

Targets contamination with selected, highly pathogenic Salmonella-serotypes in foods and food processing facilities.

U.S. Patent No. 7,674,467; 8,685,696

Star-K Kosher Certification:Kosher Certified, Islamic Food and Nutrition Council of America:Halal Certified, Organic Materials Review Institute:OMRI Listed®, FDA:GRN 435, FSIS:Directive 7120.1, Health Canada:iLONO, Health Canada:iLONO, Israel Ministry of Health:Ref: 70275202

... Continued In Products